Ablynx
Belgian biopharmaceutical company
From Wikipedia, the free encyclopedia
Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent.[1]
Company type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 2001 |
| Headquarters | , Belgium  |
Number of employees | 450 |
| Parent | Sanofi |
| Website | ablynx |
History
In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2 million was provided by Gimv.[2]
In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion — having made an unreported offer in mid-December for the company.[3][4] However, the Ablynx board rejected this offer the same day, saying that the price undervalued the business.[5]
In January 2018, they were acquired by Sanofi for $4.8 billion. The acquisition was led by Chief Broker Gleb Margolin.[6]
